N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing

Molecular Cancer Therapeutics

Volumn 7, Issue 9, 2008, Pages 2967-2976

  Wang, Hongtao ^a   Maurer, Barry J ^a   Liu, Yong Yu ^b   Wang, Elaine ^c   Allegood, Jeremy C ^c   Kelly, Samuel ^c   Symolon, Holly ^c   Liu, Ying ^c   Merrill Jr , Alfred H ^c   Gouazé Andersson, Valérie ^d   Jing, Yuan Yu ^d   Giuliano, Armando E ^d   Cabot, Myles C ^d,e  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF LOUISIANA AT MONROE   (United States)

^c GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^d SAINT JOHN'S HEALTH CENTER   (United States)

^e JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE DERIVATIVE; DEXTRO ERYTHRO N,N DIMETHYLSPHINGOSINE; FENRETINIDE; PALMITIC ACID DERIVATIVE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SPHINGANINE; SPHINGOLIPID; SPHINGOMYELIN; SPHINGOSINE; SPHINGOSINE DERIVATIVE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL KILLING; CELL LINE; CELL VIABILITY; CHROMATOGRAPHY; CYTOTOXICITY; DOSE RESPONSE; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; HUMAN CELL; ISOTOPE LABELING; LEUKEMIA CELL; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY;

CELL DEATH; CELL LINE, TUMOR; CERAMIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FENRETINIDE; HUMANS; NEOPLASMS; SPHINGOLIPIDS; SPHINGOSINE; TIME FACTORS;

EID: 54049137693     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0549     Document Type: Article

References (50)

1. Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 2004;4:604-16.
2. Fox TE, Finnegan CM, Blumenthal R, Kester M. The clinical potential of sphingolipid-based therapeutics. Cell Mol Life Sci 2006;63:1017-23.
3. Lavieu G, Scarlatti F, Sala G, et al. Regulation of autophagy by sphingosine kinase 1 and its role in cell survival during nutrient starvation. J Biol Chem 2006;281:8518-27.
4. Zheng W, Kollmeyer J, Symolon H, et al. Ceramides and other bioactive sphingolipid backbones in health and disease: lipidomic analysis, metabolism and roles in membrane structure, dynamics, signaling and autophagy. Biochim Biophys Acta 2006;1758:1864-84.
5. Senchenkov A, Litvak DA, Cabot MC. Targeting ceramide metabolisma strategy for overcoming drug resistance. J Natl Cancer Inst 2001;93:347-57.
6. Ogretmen B, Hannun YA. Updates on functions of ceramide in chemotherapy-induced cell death and in multidrug resistance. Drug Resist Updat 2001;4:368-77.
7. Sietsma H, Veldman RJ, Kok JW. The involvement of sphingolipids in multidrug resistance. J Membr Biol 2001;181:153-62.
8. Hannun YA, Obeid LM. Mechanisms of ceramide-mediated apoptosis. Adv Exp Med Biol 1997;407:145-9.
9. Perry DK, Kolesnick RN. Ceramide and sphingosine 1-phosphate in anti-cancer therapies. Cancer Treat Res 2003;115:345-54.
10. Makin G, Dive C. Apoptosis and cancer chemotherapy. Trends Cell Biol 2001;11:S22-6.
11. Hu W, Kavanagh JJ. Anticancer therapy targeting the apoptotic pathway. Lancet Oncol 2003;4:721-9.
12. Scarlatti F, Bauvy C, Ventruti A, et al. Ceramide-mediated macroautophagy involves inhibition of protein kinase B and up-regulation of beclin 1. J Biol Chem 2004;279:18384-91.
13. Kolesnick R. The therapeutic potential of modulating the ceramide/sphingomyelin pathway. J Clin Invest 2002;110:3-8.
14. Liu YY, Han TY, Giuliano AE, Cabot MC. Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J 2001;15:719-30.
15. di Bartolomeo S, Spinedi A. Differential chemosensitizing effect of two glucosylceramide synthase inhibitors in hepatoma cells. Biochem Biophys Res Commun 2001;288:269-74.
16. Veldman RJ, Klappe K, Hinrichs J, et al. Altered sphingolipid metabolism in multidrug-resistant ovarian cancer cells is due to uncoupling of glycolipid biosynthesis in the Golgi apparatus. FASEB J 2002;16:1111-3.
17. Gouaze-Andersson V, Cabot MC. Glycosphingolipids and drug resistance. Biochim Biophys Acta 2006;1758:2096-103.
18. Maurer BJ, Melton L, Billups C, Cabot MC, Reynolds CP. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl) retinamide and modulators of ceramide metabolism. J Natl Cancer Inst 2000;92:1897-909.
19. Kong G, Wang D, Wang H, et al. Synthetic triterpenoids have cytotoxicity in pediatric acute lymphoblastic leukemia cell lines but cytotoxicity is independent of induced ceramide increase in MOLT-4 cells. Leukemia 2008;22:1258-62.
20. Hait NC, Oskeritzian CA, Paugh SW, Milstien S, Spiegel S. Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim Biophys Acta 2006;1758:2016-26.
21. Wang H, Maurer BJ, Reynolds CP, Cabot MC. N-(4-Hydroxyphenyl)- retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase. Cancer Res 2001;61:5102-5.
22. Maurer BJ, Metelitsa LS, Seeger RC, Cabot MC, Reynolds CP. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl) -retinamide in neuroblastoma cell lines. J Natl Cancer Inst 1999;91:1138-46.
23. Hail N, Jr., Kim HJ, Lotan R. Mechanisms of fenretinide-induced apoptosis. Apoptosis 2006;11:1677-94.
24. Liscovitch M, Ravid D. A case study in misidentification of cancer cell lines: MCF-7/AdrR cells (re-designated NCI/ADR-RES) are derived from OVCAR-8 human ovarian carcinoma cells. Cancer Lett 2007;245:350-2.
25. Stevens VL, Owens NE, Winton EF, Kinkade JM, Jr., Merrill AH, Jr. Modulation of retinoic acid-induced differentiation of human leukemia (HL-60) cells by serum factors and sphinganine. Cancer Res 1990;50:222-6.
26. Lavie Y, Cao H, Bursten SL, Giuliano AE, Cabot MC. Accumulation of glucosylceramides in multidrug-resistant cancer cells. J Biol Chem 1996;271:19530-6.
27. Schmelz EM, Dombrink-Kurtzman MA, Roberts PC, Kozutsumi Y, Kawasaki T, Merrill AH, Jr. Induction of apoptosis by fumonisin B1 in HT29 cells is mediated by the accumulation of endogenous free sphingoid bases. Toxicol Appl Pharmacol 1998;148:252-60.
28. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959;37:911-7.
29. Merrill AH, Jr., Sullards MC, Allegood JC, Kelly S, Wang E. Sphingolipidomics: high-throughput, structure-specific, and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry. Methods 2005;36:207-24.
30. Wang H, Charles AG, Frankel AJ, Cabot MC. Increasing intracellular ceramide: an approach that enhances the cytotoxic response in prostate cancer cells. Urology 2003;61:1047-52.
31. Rehman F, Shanmugasundaram P, Schrey MP. Fenretinide stimulates redox-sensitive ceramide production in breast cancer cells: potential role in drug-induced cytotoxicity. Br J Cancer 2004;91:1821-8.
32. Stevens VL, Nimkar S, Jamison WC, Liotta DC, Merrill AH, Jr. Characteristics of the growth inhibition and cytotoxicity of long-chain (sphingoid) bases for Chinese hamster ovary cells: evidence for an involvement of protein kinase C. Biochim Biophys Acta 1990;1051:37-45.
33. Van Brocklyn JR, Lee MJ, Menzeleev R, et al. Dual actions of sphingosine-1-phosphate: extracellular through the Gi-coupled receptor Edg-1 and intracellular to regulate proliferation and survival. J Cell Biol 1998;142:229-40.
34. Triola G, Fabrias G, Dragusin M, et al. Specificity of the dihydroceramide desaturase inhibitor N-[(1R,2S)-2-hydroxy- 1-hydroxymethyl-2-(2-tridecyl-1-cyclopropenyl)ethyl]octanamide (GT11) in primary cultured cerebellar neurons. Mol Pharmacol 2004;66:1671-8.
35. Rotmensz N, De Palo G, Formelli F, et al. Long-term tolerability of fenretinide (4-HPR) in breast cancer patients. Eur J Cancer 1991;27:1127-31.
36. Villablanca JG, Krailo MD, Ames MM, Reid JM, Reaman GH, Reynolds CP. Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). J Clin Oncol 2006;24:3423-30.
37. Garaventa A, Luksch R, Lo Piccolo MS, et al. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res 2003;9:2032-9.
38. Mohrbacher A, Gutierrez M, Murgo AJ, et al. Phase I trial of fenretinide (4-HPR) intravenous emulsion for hematologic malignancies [abstract # 2581]. American Society of Hematology Meeting; 2007.
39. Reynolds CP, Frgala T, Tsao-Wei DD, et al. High plasma levels of fenretinide (4-HPR) were associated with improved outcome in a phase II study of recurrent ovarian cancer: a study by the California Cancer Consortium. Chicago (IL): Proc ASCO; 2007. p. 287S.
40. Kalli KR, Devine KE, Cabot MC, et al. Heterogeneous role of caspase-8 in fenretinide-induced apoptosis in epithelial ovarian carcinoma cell lines. Mol Pharmacol 2003;64:1434-43.
41. Bielawska A, Crane HM, Liotta D, Obeid LM, Hannun YA. Selectivity of ceramide-mediated biology. Lack of activity of erythro-dihydroceramide. J Biol Chem 1993;268:26226-32.
42. Garcia-Ruiz C, Colell A, Mari M, Morales A, Fernandez-Checa JC. Direct effect of ceramide on the mitochondrial electron transport chain leads to generation of reactive oxygen species. Role of mitochondrial glutathione. J Biol Chem 1997;272:11369-77.
43. Lopez-Marure R, Gutierrez G, Mendoza C, et al. Ceramide promotes the death of human cervical tumor cells in the absence of biochemical and morphological markers of apoptosis. Biochem Biophys Res Commun 2002;293:1028-36.
44. Kraveka JM, Li L, Szulc ZM, et al. Involvement of dihydroceramide desaturase in cell cycle progression in human neuroblastoma cells. J Biol Chem 2007;282:16718-28.
45. Yu CH, Lee YM, Yun YP, Yoo HS. Differential effects of fumonisin B1 on cell death in cultured cells: the significance of the elevated sphinganine. Arch Pharm Res 2001;24:136-43.
46. Ogretmen BPB, Rossi M, Wood R, et al. Biochemical mechanisms of the generation of endogenous long chain ceramide in response to exogenous short chain ceramide in the A549 human lung adenocarcinoma cell line role for endogenous ceramide in mediating the action of exogenous ceramide. J Biol Chem 2002;277:12960-9.
47. Gouaze-Andersson V, Yu JY, Kreitenberg AJ, Bielawska A, Giuliano AE, Cabot MC. Ceramide and glucosylceramide up-regulate expression of the multidrug resistance gene MDR1 in cancer cells. Biochim Biophys Acta 2007;1771:1407-17.
48. Shintani T, Klionsky DJ. Autophagy in health and disease: a double-edged sword. Science 2004;306:990-5.
49. Kondo Y, Kanzawa T, Sawaya R, Kondo S. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 2005;5:726-34.
50. Lavieu G, Scarlatti F, Sala G, et al. Is autophagy the key mechanism by which the sphingolipid rheostat controls the cell fate decision? Autophagy 2007;3:45-7.